Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of BM2216 Extended-Release Tablets in Healthy Adults
NCT06846567Phase 1Completed
- Sponsor
- Zhejiang Anglikang Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BM2216 in diabetic neuropathy (3 arms), sponsored by Zhejiang Anglikang Pharmaceutical. Primary endpoint: Plasma concentration of study drugs. Started Dec 2024; status: completed.
02
Drugs
BM2216
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT06846567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846567.